Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aseptika Develops Self-Monitoring, Home Lung Infection Test for People with CF

Published: Wednesday, June 26, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Company has announced that volunteers from Papworth Hospital NHS Foundation Trust are now participating in the clinical trial.

The trial incorporates the use of home telemetry to measure lung and cardiovascular function, levels of physical activity and body composition, which are combined with the measurement of biomarkers to predict the reoccurrence of chest infections.

This trial explores whether CF patients could self-monitor at home, with remote support from their clinicians, using the Company’s home infection test and the Activ8rlives web-based platform.

The Company successfully bid for and was awarded Phase 1 funding through NHS Midlands and East and the Health Enterprise East's second SBRI competition in 2011. In May of last year, Aseptika was also awarded Phase 2 funding to undertake this current study.

The company has already demonstrated the feasibility of quantifying the levels of key biomarkers in sputum samples as a way of predicting the onset of chest infections known clinically as 'exacerbations'. The biomarker tests can be used to give both clinicians and patients 7 to 10 days advanced warning of an exacerbation and when commercialised, could lead to a reduction in hospital admissions and length of stay, as well as improving healthcare outcomes for those with CF.

In the trial, volunteers measure key performance indicators of health such as Peak Flow, FEV1, pO2, heart rate, physical activity, weight, body composition, cough and wellness at home and this information is uploaded to their private Activ8rlives web account. The sputum profiling data is added to this same web database and correlated with the volunteer’s medication regime. This wealth of information can be viewed by the clinician for research purposes only at this stage during the trial, but will be made available to the patients at its completion.

In a comment on the current clinical trial, Dr. Anne Blackwood, Chief Executive of Health Enterprise East said, “Aseptika's technology platform has the potential to improve the quality of life of patients with CF in addition to reducing healthcare costs by preventing unnecessary admissions. Empowering patients to self-manage their condition is a key priority for the NHS.”

The objective of the self-monitoring solution being developed by Aseptika is to provide the tools to CF patients and their carers to help them stay well. Simultaneously this also provides their clinical team with complete, reliable and up to date information, especially for patients which have long journeys to attend their specialty clinics. Early changes in levels of biomarkers and health indicators will give patients, their families and clinicians every chance to identify when a course of treatment is becoming ineffective or when a change in treatment is required, or identify if additional support at home is needed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!